VanEck Pharmaceutical ETF PPH

Morningstar Medalist Rating

Morningstar’s Analysis PPH

Will PPH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings72.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

23.10254M
Healthcare

Merck & Co Inc

12.12133M
Healthcare

Novo Nordisk AS ADR

5.5060M
Healthcare

McKesson Corp

5.0155M
Healthcare

Teva Pharmaceutical Industries Ltd

4.7853M
Healthcare

Pfizer Inc

4.6851M
Healthcare

Cencora Inc

4.5049M
Healthcare

Bristol-Myers Squibb Co

4.4349M
Healthcare

GSK PLC ADR

4.2046M
Healthcare

AbbVie Inc

3.6640M
Healthcare

Sponsor Center